Şunu aradınız:: laryngeal (İngilizce - Maltaca)

laryngeal pain
uġigħ fil-larinġi

laryngeal oedema
edima fil-larinġi

pharyngo laryngeal pain
uġigħ farinġjo-laringeali

laryngeal pain, snoring
uġigħ fil-larinġi, inħir

stridor, laryngeal oedema
stridor, edema larinġeali

rare: dyspnoea, laryngeal oedema.
rari: dispnea, edema larinġeali.

laryngeal oedema, hypoxia, tachypnoea
edima fil-larinġi, nuqqas ta’ ossiġnu, takipneja

laryngeal oedemae, dyspnoeab,c,e,
edima fil-larinġie, qtugħ ta’ nifsb,ċ,e,

rhinitis nasal congestion pharyngo laryngeal pain
farinġite rinite konġestjoni nażali uġigħ farinġjo- laringeali

angioedema associated with laryngeal oedema may be fatal.
anġjoedima assoċjata ma’ edima larinġali tista’ tkun fatali.

angioedema accompanied by laryngeal oedema is potentially fatal.
anġjoedema akkumpanjata minn edema larinġeali hi potenzjalment fatali.

erythema, facial edema, laryngeal edema, edema peripheral
eritema, edema fil-wiċċ, edema fil-larinġi, edema periferali

patients with symptoms of laryngeal angioedema received open label treatment with icatibant.
il-pazjenti b’sintomi ta’ anġjoedema larinġali rċevew trattament open label b’icatibant.

among 84 separate laryngeal hae attacks, none required intubation following treatment with cinryze.
fost 84 attakki larinġeali separati ta’ hae, l-ebda wieħed minnhom ma kien jeħtieġ intubazzjoni wara l-kura b’cinryze.

among 15 subjects treated with open-label cinryze for laryngeal hae attacks, none required intubation.
fost il-15-il persuna kkurati b’cinryze open-label għal attakki ta’ hae larinġeali, l-ebda waħda minnhom ma kienet teħtieġ intubazzjoni.

allergic reactions, anaphylaxis including dyspnoea, bronchospasm, laryngeal oedema, in rare cases leading to shock.
reazzjonijiet allerġiċi, anafilassi fosthom dispneja, bronkospażmu, edema fil-larinġi, li f’każijiet rari jwasslu għal xokk.

for patients experiencing laryngeal attacks or if initiation of treatment is delayed, the second dose can be given sooner than 60 minutes.
għal pazjenti li jkollhom attakki larinġeali, jew jekk il-bidu tal-kura jiġi ttardjat, it-tieni doża tista’ tingħata qabel ma jgħaddu 60 minuta.

serious adverse reactions included laryngeal edema, apnoea, pyrexia, urticaria, respiratory distress, angioedema, asthma and anaphylactoid reaction.
reazzjonijiet avversi serji kienu jinkludu edima fil-larinġi, apnea, deni, urtikarja, distress respiratorju, anġjoedima, ażżma u reazzjoni anafilattojda.

dyspnoea, dysphonia, rhinorrhoea, throat tightness, bronchospasm, cough, laryngeal/pharyngeal oedema, pharyngitis, rhinitis, sneezing
dispneja, disfonija, Ħruġ ta’ likwidu mill-imnieħer, dwejjaq fil-gerżuma, bronkospażmu, sogħla, edema tal- farinġi/larinġi, farinġite, rinite, għatis

firazyr should be used during pregnancy only, if the potential benefit justifies the potential risk for the foetus, (e.g for treatment of potentially life threatening laryngeal attacks).
firazyr għandu jintuża waqt it-tqala biss jekk il-benefiċċju potenzjali jiġġustifika r-riskju li jista’ jkun hemm għall-fetu (eż. għat-trattament ta’ attakki fil-larinġi li jistgħu jkunu ta’ periklu għall-ħajja).